Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lb80380. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lb80380 SCHEMBL4270816 | 1.00 | FAP (0.46) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL2906952 | 0.95 | ABCB11 (0.42) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL13178775 | 0.94 | ABCB11 (0.41) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL2912291 | 0.92 | ABCB11 (0.42) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL26287379 | 0.89 | ABCB11 (0.40) | FAPABCB11POLA1POLGSLC22A6 | |
| Maleic Acid SCHEMBL4395451 | 0.89 | FAP (0.40) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL4415990 | 0.89 | ABCB11 (0.40) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL4419762 | 0.89 | ABCB11 (0.40) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL4268756 | 0.89 | FAP (0.46) | FAPABCB11POLA1POLGSLC22A6 | |
| SCHEMBL2912858 | 0.88 | KDM4E (0.44) | FAPABCB11POLA1POLGSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-20250145680-A1 | NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF | REMD BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | claimed |
| EP-4526338-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4526339-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119546629-A | Compositions and methods for treating Hepatitis Delta Virus (HDV) infection and related diseases | 维尔生物科技公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119403827-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection and HBV related diseases | 维尔生物科技公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4412636-A2 | NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF | REMD Biotherapeutics, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| CN-118201953-A | Novel interferon variants and bifunctional fusion molecules thereof | 瑞美德生物医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-110913898-B | Methods of treating subjects having Hepatitis B Virus (HBV) infection | 阿尔尼拉姆医药品有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116390943-A | Engineered hepatitis b virus neutralizing antibodies and uses thereof | 维尔生物科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4171747-A1 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | VIR Biotechnology, Inc. (US) | 2023-05-03 | — | — | EP | claimed |
| WO-2023023283-A2 | NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF | REMD BIOTHERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | claimed |
| US-20220339256-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. | 2022-10-27 | — | — | US | claimed |
| WO-2022160323-A1 | APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES | 兰州大学 | 2022-08-04 | — | — | WO | claimed |
| WO-2022108094-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | 주식회사 차백신연구소 | 2022-05-27 | — | — | WO | claimed |
| CN-114533739-A | Application of nucleoside analogue in preparing medicine for preventing or treating gastrointestinal tract diseases | 兰州大学 | 2022-05-27 | — | — | CN | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | FAP 3561/4885ABCB11 2223/4885POLA1 260/4885 |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HAVCR2, HLA-B, HDGF | FAP 1447/4885ABCB11 751/4885POLA1 456/4885 |
| US-20220339256-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | HAVCR2, HDGF, IFNG | FAP 1021/4885ABCB11 1238/4885POLA1 792/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | FAP 3497/4885ABCB11 1664/4885POLA1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.